Financial Performance - Total revenue for 2024 reached RMB 269,765.79 million, a year-on-year increase of 1.64%[4] - Net profit attributable to shareholders was RMB 42,015.41 million, reflecting a growth of 0.97% compared to the previous year[4] - Basic earnings per share rose to RMB 1.80, up 2.86% from RMB 1.75 in the previous year[4] - The net profit excluding non-recurring gains and losses was RMB 38,120.90 million, a slight decrease of 0.57% year-on-year[4] - The weighted average return on net assets was 7.41%, an increase of 0.02 percentage points from the previous year[4] Assets and Equity - The company's total assets at the end of the reporting period were RMB 712,469.06 million, an increase of 0.27% from the beginning of the period[7] - The equity attributable to shareholders decreased by 1.20% to RMB 558,244.99 million[7] - The company's share capital increased by 35.99% to RMB 23,319.37 million due to the issuance of 66,782,692 new shares in June 2024[8] Operational Strategy - The company focused on optimizing product structure and enhancing operational efficiency to improve profitability[7] Audit and Reporting - The financial data presented is preliminary and subject to final audit in the annual report[9]
昊海生科(688366) - 2024 Q4 - 年度业绩